15 related news articles for
-
MRFF funding advances Hudson Institute RNA therapies
Hudson Institute of Medical Research has been recognised as a leader in RNA based medicine, with new federal government funding set to accelerate the search for new and better treatments.… Read more
-
Genetic changes identified as key to childhood lupus
Hudson Institute researcher Professor Seth Masters, working with colleagues at China’s Guangzhou Women and Children’s Medical Center, has identified a specific genetic variant which contributes to the development of childhood-onset lupus.… Read more
-
Better treatments sooner: Hudson unveils RNAte Platform
Hudson Institute of Medical Research today officially unveiled its world-first RNAte platform that could see vaccines and therapeutic treatments developed faster by being able to rapidly assess their potential inflammation side effects, right here in Victoria.… Read more
-
Searching for clues to how RNA triggers the immune system
A young Melbourne scientist will spend the next three years advancing exiting new mRNA research to unlock the secrets to how RNA triggers the immune system to fight infection.… Read more
-
Soy molecule may lead to new anti-inflammatory drug
A naturally occurring molecule found in soy products could hold the clue to a new class of potent anti-inflammatory drugs, targeting diseases ranging from heart conditions to COVID-19.… Read more
-
RNA boost for autoimmune disease
The enormous potential of RNA-based treatments for autoimmune diseases has been recognised by the Victorian government, with a new grant from the mRNA Victoria Research Acceleration Fund.… Read more
-
Australian scientists find genetic cause of lupus
An international study that found a novel genetic cause of lupus owes much of its success to a single lab in Melbourne.… Read more
-
Making more effective and efficient RNA therapeutics
RNA technology developed by Hudson Institute of Medical Research with the potential to limit inflammatory side-effects of RNA therapeutics such as mRNA vaccines, is the subject of a new licensing deal.… Read more
-
Flicking the inflammation off-switch
Many human diseases, including autoimmune diseases such as arthritis or inflammatory bowel disease, are characterised by too much inflammation.
There has been a gap in producing new generations of potent anti-inflammatory therapeutics for these anti-inflammatory conditions.… Read more -
Discovery opens up new RNA therapies for diseases driven by auto-inflammation
RNA therapeutics comprise a rapidly expanding category of drugs that have the potential to revolutionise treatments for many diseases, including those currently deemed undruggable.… Read more
-
Hyper-acute inflammation in COVID-19
Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.… Read more
-
Unearthing a new form of toxic inflammation
Hudson Institute scientists have discovered how a molecule is transferred between damaged cells and healthy immune cells, which might cause toxic inflammation in a host of diseases.… Read more
-
Paving the way towards a new anti-inflammatory agent
Hudson Institute researchers provide new insights into how the IL-37 protein blocks inflammation—emphasising the potential for a novel treatment in the fight against a plethora of inflammatory diseases.… Read more
-
Stunning NHMRC Grant success
Hudson Institute has had outstanding success in the recent NHMRC Project Grant round. In addition, our researchers have been awarded an NHMRC Partnership Grant, an NHMRC Development Grant, an ARC Discovery Grant and three NMHRC Fellowships.… Read more
-
Scientists override the body’s inflammatory response
Scientists who have discovered the mechanism of a protein that suppresses inflammation in the body, say the information could potentially be used to develop new drugs to control inflammation.… Read more